Growth Capital • Life Science

The BroadOak Fund Invests In CDI Laboratories

On January 9, 2023, growth capital firm The BroadOak Fund invested in life science company CDI Laboratories

Investment Context

This is The BroadOak Fund’s 20th transaction in the Life Science sector.
This is The BroadOak Fund’s 1st transaction in Puerto Rico.

Explore All 400 Growth Capital Life Science Deals - Search the Database Free

Investment Summary
Date	January 9, 2023
Target	CDI Laboratories
Sector	Life Science
Investor(s)	The BroadOak Fund
Deal Type	Growth Capital

Target Company

CDI Laboratories

Mayaguez, Puerto Rico

CDI Laboratories is the nextGen proteomics company, a result of intensive efforts and advances made by synthetic biologists at the Johns Hopkins University School of Medicine. The company was created by scientists for scientists to address critical needs required accelerate research, advance discoveries, and translate these discoveries into novel products and services that improve human health. CDI Laboratories is based in Mayaguez, Puerto Rico.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Investor Overview 1

Investor

The BroadOak Fund

Investor Investor

Category	Growth Capital Firm
Size	Small
Type	Sector Focused

DESCRIPTION

The BroadOak Fund is the investment affiliate of life science focused investment bank BroadOak Capital Partners. The BroadOak Fund provides growth capital to life sciences tools and service providers that have achieved a level of commercial success. The BroadOak Fund is based in Bethesda, Maryland.

Deal Context for Investor	#
Overall	25 of 26
Sector: Life Science	20 of 21
Type: Growth Capital	14 of 14
Country: Puerto Rico	1 of 1
Year: 2023	2 of 2

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2023-01-09	Sanguine BioSciences Woburn, Massachusetts, United States Sanguine BioSciences engages in-home specimen collection and a leader in direct-to-patient recruitment and digital health innovation. Sanguine BioSciences bridging the gap between patients and researchers to accelerate discovery and development. Sanguine BioSciences is based in Woburn, Massachusetts.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2023-01-09

Sanguine BioSciences

Woburn, Massachusetts, United States

Sanguine BioSciences engages in-home specimen collection and a leader in direct-to-patient recruitment and digital health innovation. Sanguine BioSciences bridging the gap between patients and researchers to accelerate discovery and development. Sanguine BioSciences is based in Woburn, Massachusetts.

Buy

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2024-01-23	Emvenio Research Durham, North Carolina, United States Emvenio Research is a decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Emvenio Research is based in Durham, North Carolina.	Sell	-

DATE

TARGET

DEAL TYPE

VALUE

2024-01-23

Emvenio Research

Durham, North Carolina, United States

Emvenio Research is a decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Emvenio Research is based in Durham, North Carolina.

Sell

Explore Related M&A Activity

Life Science M&A - Growth Capital M&A Deals - Puerto Rico M&A - 2023 M&A